The Role of RAGE in Aminoguanidine-Induced Suppression of Venous Intimal Hyperplasia in Diabetic Rats

Annals of Vascular Surgery

Volumn 23, Issue 2, 2009, Pages 246-254

  Wang, Xin ^a   Diao, Yanpeng ^b   Zhang, Hongwei ^a   Huo, Xin ^a   Zhang, Qiang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXTERNAL JUGULAR VEIN; HYPERPLASIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VEIN GRAFT;

ANIMALS; AORTA, ABDOMINAL; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GRAFT OCCLUSION, VASCULAR; GUANIDINES; HYPERPLASIA; JUGULAR VEINS; MALE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TUNICA INTIMA; VASCULAR SURGICAL PROCEDURES;

EID: 62249222502     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2008.09.004     Document Type: Article

References (33)

1. Nwasokwa O.N. Coronary artery bypass graft disease. Ann Intern Med 123 (1995) 528-533
2. Eugster T., Stierli P., and Aeberhard P. Infrainguinal arterial reconstruction with autologous vein grafts: are the results for the in situ technique better than those of non-reversed bypass? A long-term follow-up study. J Cardiovasc Surg 42 (2001) 221-226
3. Halloran B.G., Lilly M.P., Cohn E.J., et al. Tibial bypass using complex autologous conduit patency and limb salvage. Ann Vasc Surg 15 (2001) 634-643
4. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
5. Sasaki Y., Suehiro S., Becker A.E., et al. Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart 83 (2000) 69-75
6. Shi Y., O'Brien Jr. J.E., Mannion J.D., et al. Remodelling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 95 (1997) 2684-2693
7. Ashfaq S., Ghazzal Z., Douglas J.S., et al. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive Cardiol 18 (2006) 100-105
8. Engelhardt M., Bruijnen H., Scharmer C., et al. Improvement of quality of life six months after infrageniculate bypass surgery: diabetic patients benefit less than non-diabetic patients. Eur J Vasc Endovasc Surg 32 (2006) 182-187
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
10. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267 (1992) 14998-15004
11. Nawroth P., Bierhaus A., Marrero M., et al. Atherosclerosis and restenosis: is there a role for RAGE?. Curr Diab Rep 5 (2005) 11-16
12. Liu S.Q. Prevention of focal intimal hyperplasia in rat vein grafts by using a tissue engineering approach. Atherosclerosis 140 (1998) 365-377
13. Wang B., Wang X.W., and Duan Z.Q. Mithramycin inhibits intimal hyperplasia of vein grafts after transplantation of the jugular vein to the abdomainal aorta in rats. Chin J Traumatol 3 (2000) 172-175
14. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
15. Stern D.M., Yan S.D., Yan S.F., et al. Receptor for advanced glycation end products (RAGE) and the complications of diabetes. Ageing Res Rev 1 (2002) 1-15
16. Naka Y., Bucciarelli L.G., Wendt T., et al. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24 (2004) 1342-1349
17. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
18. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumor growth and metastases. Nature 405 (2000) 354-360
19. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
20. Yeh C.H., Sturgis L., Haidacher J., et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50 (2001) 1495-1504
21. Bourcier T., Sukhova G., and Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272 (1997) 15817-15824
22. Brand K., Page S., Rogler G., et al. Activated transcription factor nuclear factor-kappaB is present in the atherosclerotic lesion. J Clin Invest 97 (1996) 1715-1722
23. Selzman C.H., Shames B.D., Reznikov L.L., et al. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84 (1999) 867-875
24. Miyake T., Aoki M., Shiraya S., et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol 41 (2006) 431-440
25. Lorusso R., Pentiricci S., Raddino R., et al. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes 52 (2003) 2814-2820
26. Salzberg S.P., Filsoufi F., Anyanwu A., et al. Increased neointimal formation after surgical vein grafting in a murine model of type 2 diabetes. Circulation 114 Suppl. I (2006) I302-I307
27. Ozmen O., Topsakal S., Sahinduran S., et al. Effect of insufficient insulin treatment in streptozotocin-induced diabetes mellitus. Pancreas 34 (2007) 354-358
28. Sun M., Yokovama M., Ishiwata T., et al. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Pathol 79 (1998) 207-222
29. Sakaguchi T., Yan S.F., Yan S.D., et al. Arterial restenosis: central role of RAGE-dependent neointimal expansion. J Clin Invest 111 (2003) 959-972
30. Duraisamy Y., Gaffney J., Slevin M., et al. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation end products and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine. Mol Cell Biochem 246 (2003) 143-153
31. Chyu K.Y., Dimayuga P., Zhu J., et al. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 85 (1999) 1192-1198
32. Cable D.G., Caccitolo J.A., Caplice N., et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 100 Suppl. 19 (1999) II392-II396
33. Janssens S., Flaherty D., Nong Z., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97 (1998) 1274-1281